Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
PLoS One. 2013 Dec 4;8(12):e82650. doi: 10.1371/journal.pone.0082650. eCollection 2013.
Recent studies have highlighted the role of androgen receptor (AR) as a prognostic biomarker of breast cancer. However, its predictive role in disease free survival (DFS) and overall survival (OS) still remains inconclusive. The present study aimed to retrospectively investigate the association between AR and survival outcomes in breast cancer and also identify this association by a meta-analysis of published researches. Clinical data from 109 patients with breast cancer, who underwent surgery at Ruijin Hospital, Shanghai, were retrospectively analyzed for immunohistochemical AR expression measured by tissue microarray. For meta-analysis, articles available in Pubmed on the relationship between AR and breast cancer outcomes were included. Data obtained from both were combined and analyzed. Women with AR positive tumors in the retrospective study had a significantly better DFS (HR 0.24, 95% CI 0.07-0.88) and OS (HR 0.19, 95% CI 0.04-0.85) than women with AR negative ones. Meta-analysis showed that AR expression in breast tumors was an indicator of better DFS (HR 0.52, 95% CI 0.43-0.64). In subgroup analysis, AR could predict DFS outcome in estrogen receptor (ER) positive (HR 0.45, 95% CI 0.34-0.59), ER negative (HR 0.42, 95% CI 0.26-0.67), and triple negative breast cancer (HR 0.40, 95% CI 0.23-0.69). Moreover, in ER positive breast cancer patients, the expression of AR could predict better OS (HR 0.39, 95% CI 0.19-0.82). The present analysis indicated that AR expression was associated with lower risk of recurrence in patients with all breast cancer types and better OS in cases with ER positive.
最近的研究强调了雄激素受体 (AR) 作为乳腺癌预后生物标志物的作用。然而，其在无病生存期 (DFS) 和总生存期 (OS) 中的预测作用仍不确定。本研究旨在回顾性研究 AR 与乳腺癌生存结局的关系，并通过对已发表研究的荟萃分析来确定这种关系。对在上海瑞金医院接受手术的 109 例乳腺癌患者的临床数据进行回顾性分析，通过组织微阵列测量免疫组织化学 AR 表达。对于荟萃分析，纳入了 Pubmed 上关于 AR 与乳腺癌结局关系的文章。从这两个来源获得的数据进行了组合和分析。在回顾性研究中，AR 阳性肿瘤的女性 DFS（HR 0.24，95%CI 0.07-0.88）和 OS（HR 0.19，95%CI 0.04-0.85）显著优于 AR 阴性者。荟萃分析表明，乳腺癌肿瘤中 AR 的表达是 DFS 更好的指标（HR 0.52，95%CI 0.43-0.64）。在亚组分析中，AR 可以预测 ER 阳性（HR 0.45，95%CI 0.34-0.59）、ER 阴性（HR 0.42，95%CI 0.26-0.67）和三阴性乳腺癌（HR 0.40，95%CI 0.23-0.69）患者的 DFS 结局。此外，在 ER 阳性乳腺癌患者中，AR 的表达可以预测更好的 OS（HR 0.39，95%CI 0.19-0.82）。本分析表明，AR 表达与所有乳腺癌类型患者的复发风险降低相关，在 ER 阳性患者中与更好的 OS 相关。
